PRINCETON, N.J., July 22, 2014 /PRNewswire/ -- Geistlich Pharma North America is pleased to announce that Dr. Peter Geistlich, Chairman of the Board, Geistlich Pharma AG was presented with Loma Linda University's Distinguished Humanitarian Award on May 25, 2014.
The award recognized Dr. Geistlich as an "internationally renowned pioneer in materials research, global leader in regenerative medicine, and passionate advocate for high quality research and education that translate into improved patient outcomes. His generous philanthropic engagement supports advancement of the University's model 'to make man whole'".
Dr. Geistlich shares an enduring and vibrant bond with the University, built through decades of scientific collaboration with Professor Philip Boyne. Together, their commitment to advancing quality of care in the fields of oral and maxillofacial surgery and tissue regeneration led to the joint creation and the funding of the Boyne-Geistlich Professorship in Oral and Maxillofacial Surgery at The School of Dentistry.
"It is a highlight in my life to be honored by this very fine university and to have had the opportunity to collaborate on research projects for many years with Dr. Philip Boyne and now with Dr. Alan Herford. For me it is a joy to participate in and to support quality research. I have always been very impressed with the innovative research activities and the quality results that the Loma Linda University School of Dentistry has generated," said Dr. Peter Geistlich, Chairman of the Board, Geistlich AG.
"The company is very thankful and proud of Dr. Geistlich's many accomplishments. It is through the collaboration with Dr. Phillip Boyne and Loma Linda University that many of our product innovations were born. The result has been scientifically proven products that have helped millions of dentists and their patients worldwide," said Mr. Greg Bosch, CEO, Geistlich Pharma North America.
About Dr. Peter Geistlich:
Dr. Peter Geistlich studied organic chemistry at the Federal Institute of Chemistry in Zurich, Switzerland and in 1955 joined the family business, which was founded in 1851 by Eduard Geistlich. Peter Geistlich had an early passion for research and while he is still an active researcher his current position is Chairman of the Board of Geistlich.
Dr. Geistlich is a pioneer in biomaterial research and his overriding objective is to develop products based on scientific principles, long-term research and the ability to make a difference to a patient's life. Dr. Geistlich and Dr. Boyne shared a lifelong friendship and scientific research collaboration. The sharing of a common goal to improve the quality of care in the fields of oral and maxillofacial surgery and tissue regeneration lead to the joint creation and funding of the Boyne-Geistlich Professorship in Oral and Maxillofacial Surgery at The School of Dentistry.
As evidence to his commitment to science, in 2003 Dr. Geistlich and Geistlich Pharma AG founded the independent and Swiss based Osteology Foundation to link science with practice in regenerative dentistry. In 2013 the Philadelphia based Osteo Science Foundation was formed to provide research funding and education to accelerate innovation and development of novel biomaterials.
About Geistlich Pharma
Founded 160 years ago, as Geistlich Sons Ltd., our respected family-owned Swiss company has pioneered technological advances that make regenerative treatment with our biomaterials the preferred choice for clinical predictability. Today Geistlich Pharma, affiliate of Geistlich Sons Ltd., is the leader in regenerative dentistry. Our product family includes bone substitute Geistlich Bio-Oss®, the resorbable bilayer collagen membrane, Geistlich Bio-Gide® and the 3 dimensional matrix, Geistlich Mucograft®.
For more information, visit www.geistlich-na.com
SOURCE Geistlich Pharma